VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2 Sep 13, 2021
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update Aug 12, 2021
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021 Aug 9, 2021
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors Jul 22, 2021
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Jun 29, 2021
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021 Jun 25, 2021
